Coya Therapeutics Publishes Study on Biomarkers and ALS Treatment Efficacy
Coya Therapeutics has published a study demonstrating the correlation between certain biomarkers and clinical outcomes in patients with Amyotrophic Lateral Sclerosis (ALS). The study, led by Dr. David Beers and Dr. Stanley Appel, evaluated biomarkers such as 4-hydroxy-2-nonenal, lipopolysaccharide binding protein, and neurofilament light chain in ALS patients. The findings suggest these biomarkers are significantly correlated with disease progression and survival rates. The study supports the mechanistic rationale for Coya's investigational therapy, COYA 302, which aims to enhance regulatory T cell function to combat inflammation in ALS. 
